Article
25 Oct 2024
Federal Circuit Denies Injunction Pending Appeal After Amgen Beat Preliminary Injunction For Biosimilar Aflibercept
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
16 Aug 2024
Recent PTAB Developments For Regeneron's Aflibercept-Dosing Patents
Article
05 Feb 2024
Celltrion Launches 80 Mg YUFLYMA (Adalimumab-aaty) In The U.S.
Article
20 Nov 2023
Regeneron Sues Celltrion For Proposed Biosimilar Of Eylea In West Virginia District Court
Article
06 Jul 2023
Formycon And Celltrion Announce FDA Submission Of ABLAs Seeking Approval To Market Aflibercept Biosimilars
Article
14 Dec 2022
Regeneron Files Expedited Motion Challenging Mylan's Designation Of Entire ABLA Production As Outside Counsel's Eyes Only
Article
04 Aug 2022
Regeneron Files First BPCIA Complaint Regarding Biosimilar Eylea Against Mylan In West Virginia District Court
Article
14 Jul 2022
CA Gov. Newsom Announces Budget Approval For Biosimilar Insulin Initiative